At close: December 13 at 1:30:03 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,591,819.00
4,360,448.00
3,765,504.00
3,142,406.00
3,075,457.00
Cost of Revenue
2,576,828.00
2,437,119.00
2,375,312.00
2,170,962.00
2,130,287.00
Gross Profit
2,014,991.00
1,923,329.00
1,390,192.00
971,444.00
945,170.00
Operating Expense
1,290,504.00
1,274,817.00
1,198,355.00
1,153,333.00
886,429.00
Operating Income
724,487.00
648,512.00
191,837.00
-181,889.00
58,741.00
Net Non Operating Interest Income Expense
-13,943.00
-11,027.00
-17,175.00
-27,694.00
-27,453.00
Pretax Income
410,677.00
142,391.00
333,181.00
1,087,526.00
361,168.00
Tax Provision
155,197.00
194,650.00
116,371.00
44,008.00
31,990.00
Net Income Common Stockholders
392,864.00
126,243.00
409,359.00
1,249,096.00
400,034.00
Diluted NI Available to Com Stockholders
392,864.00
126,243.00
409,359.00
1,249,096.00
400,034.00
Basic EPS
3.27
1.05
3.40
10.92
3.78
Diluted EPS
3.26
1.05
3.39
10.32
3.46
Basic Average Shares
120,256.00
120,256.00
120,256.00
114,356.00
105,659.00
Diluted Average Shares
120,937.36
120,491.00
120,884.00
121,497.00
118,199.00
Total Expenses
3,867,332.00
3,711,936.00
3,573,667.00
3,324,295.00
3,016,716.00
Net Income from Continuing & Discontinued Operation
392,864.00
126,243.00
409,359.00
1,249,096.00
400,034.00
Normalized Income
407,084.46
105,072.60
427,805.82
1,235,785.35
428,040.31
Interest Income
29,824.00
23,708.00
2,144.00
357.00
1,067.00
Interest Expense
43,767.00
34,735.00
19,319.00
28,051.00
28,520.00
Net Interest Income
-13,943.00
-11,027.00
-17,175.00
-27,694.00
-27,453.00
EBIT
454,444.00
177,126.00
352,500.00
1,115,577.00
389,688.00
EBITDA
960,944.00
665,455.00
823,415.00
1,590,576.00
839,499.00
Reconciled Cost of Revenue
2,576,828.00
2,437,119.00
2,375,312.00
2,170,962.00
2,130,287.00
Reconciled Depreciation
506,500.00
488,329.00
470,915.00
474,999.00
449,811.00
Net Income from Continuing Operation Net Minority Interest
392,864.00
126,243.00
409,359.00
1,249,096.00
400,034.00
Total Unusual Items Excluding Goodwill
-22,859.00
26,463.00
-28,348.00
13,872.00
-30,728.00
Total Unusual Items
-22,859.00
26,463.00
-28,348.00
13,872.00
-30,728.00
Normalized EBITDA
983,803.00
638,992.00
851,763.00
1,576,704.00
870,227.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-8,638.54
5,292.60
-9,901.18
561.35
-2,721.69
12/31/2020 - 2/28/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
1795.TW Lotus Pharmaceutical Co., Ltd.
261.00
-1.51%
6472.TW Bora Pharmaceuticals Co., LTD.
751.00
-0.79%
6446.TW PharmaEssentia Corporation
585.00
-1.85%
4123.TWO Center Laboratories, Inc.
42.95
-1.72%
4119.TW SCI Pharmtech, Inc.
90.60
-2.05%
4105.TWO TTY Biopharm Company Limited
73.20
-1.48%
4120.TWO Orient EuroPharma Co., Ltd.
48.50
-8.14%
1720.TW Standard Chemical & Pharmaceutical Co. Ltd.
63.00
-1.56%
3705.TW YungShin Global Holding Corporation
54.20
-1.09%
1789.TW ScinoPharm Taiwan, Ltd.
22.20
-2.20%